Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rang în acțiuni #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Preț acțiune
$0.25974701
Ultima sincronizare: 2025-01-06
Capitalizare de piață
$2.04M
Schimbare (1 zi)
0.74%
Schimbare (1 an)
0.00%
Țară
FR
Tranzacționează Acticor Biotech SAS (ALACT)

Categorie

EPS pentru Acticor Biotech SAS (ALACT)
EPS la data de June 2024 TTM: $-1.95
Conform celor mai recente rapoarte financiare și prețului acțiunilor Acticor Biotech SAS, EPS-ul actual al companiei (TTM) este $-1.95. La sfârșitul anului 2022, compania avea un EPS de $-1.62 o scădere comparativ cu EPS-ului din 2021, care a fost de $-1.84.
Istoricul EPS pentru Acticor Biotech SAS din 2010 până în 2026
EPS la sfârșitul fiecărui an
An EPS Schimbă
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
EPS pentru companii similare sau concurente
Companie EPS Diferență EPS Țara
$17.32 -986.39%
US
$27.74 -1,519.65%
NL
$-5.29 170.73%
AU
$-7.98 308.39%
US
- -
CH